- Home
- AUST vs AYTU Comparison
AUST vs AYTU Comparison
Compare AUST & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- AYTU
- Stock Information
- Founded
- AUST 2020
- AYTU N/A
- Country
- AUST Canada
- AYTU United States
- Employees
- AUST N/A
- AYTU N/A
- Industry
- AUST
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- AYTU Health Care
- Exchange
- AUST Nasdaq
- AYTU Nasdaq
- Market Cap
- AUST 22.2M
- AYTU 20.5M
- IPO Year
- AUST 2022
- AYTU N/A
- Fundamental
- Price
- AUST $1.75
- AYTU $2.12
- Analyst Decision
- AUST
- AYTU Strong Buy
- Analyst Count
- AUST 0
- AYTU 3
- Target Price
- AUST N/A
- AYTU $9.17
- AVG Volume (30 Days)
- AUST 89.9K
- AYTU 59.2K
- Earning Date
- AUST 11-06-2025
- AYTU 11-13-2025
- Dividend Yield
- AUST N/A
- AYTU N/A
- EPS Growth
- AUST N/A
- AYTU N/A
- EPS
- AUST N/A
- AYTU N/A
- Revenue
- AUST N/A
- AYTU $63,696,000.00
- Revenue This Year
- AUST N/A
- AYTU N/A
- Revenue Next Year
- AUST N/A
- AYTU $29.12
- P/E Ratio
- AUST N/A
- AYTU N/A
- Revenue Growth
- AUST N/A
- AYTU N/A
- 52 Week Low
- AUST $1.05
- AYTU $0.95
- 52 Week High
- AUST $2.94
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- AUST 52.71
- AYTU 49.95
- Support Level
- AUST $1.42
- AYTU $1.91
- Resistance Level
- AUST $1.69
- AYTU $2.15
- Average True Range (ATR)
- AUST 0.17
- AYTU 0.13
- MACD
- AUST 0.02
- AYTU 0.01
- Stochastic Oscillator
- AUST 88.01
- AYTU 53.37
About AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.